Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEOLAIR vs AEROLATE III
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline, the active ingredient in THEOLAIR, is a phosphodiesterase inhibitor that increases intracellular c AMP levels, leading to bronchodilation via smooth muscle relaxation. It also has anti-inflammatory effects and may enhance diaphragmatic contractility.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma,Treatment of chronic obstructive pulmonary disease (COPD)
Treatment and prophylaxis of bronchospasm associated with asthma, chronic bronchitis, and emphysema,Off-label: Apnea of prematurity (oral/IV theophylline)
Initial dose: 300 mg orally every 8-12 hours; titrate based on serum theophylline levels to achieve 5-15 mcg/m L. Maintenance: 400-600 mg/day in divided doses.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
Adults: 3-8 hours (mean 5.5); children: 1.5-5 hours; increased in hepatic cirrhosis, heart failure, and COPD; decreased in smokers
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Primarily hepatic via CYP1A2 and CYP3A4; also metabolized by N-demethylation and oxidation. Approximately 10% excreted unchanged in urine.
Primarily hepatic via cytochrome P450 1A2 (CYP1A2); also CYP2E1 and CYP3A4; exhibits nonlinear pharmacokinetics.
Renal (10% unchanged); hepatic metabolism (90%) with metabolites excreted in urine
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
40% bound, primarily to albumin
92-96%, primarily to albumin and alpha-1-acid glycoprotein
0.45 L/kg; approximates total body water; higher in infants
Vd 1.5-2.0 L/kg, indicating extensive tissue distribution
Oral: 96% (immediate release); sustained release: 80-100%
Oral: 40-50%; Inhalation: 20-30%
GFR < 30 m L/min: reduce dose by 50% and monitor serum levels. GFR 30-50 m L/min: reduce dose by 25%.
No adjustment needed for GFR >30 m L/min. For GFR 10-30 m L/min: use 50% of usual dose. For GFR <10 m L/min: avoid use.
Child-Pugh Class B: reduce dose by 50%. Class C: reduce dose by 75% or use alternative.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Children 1-9 years: starting dose 10-16 mg/kg/day orally in divided doses every 4-6 hours; max 600 mg/day. Children 9-16 years: 10-16 mg/kg/day; max 800 mg/day. Adjust based on serum levels (5-15 mcg/m L).
Children 2-11 years: 1 inhalation (100 mcg) twice daily via metered-dose inhaler. Children 12 years and older: same as adult.
Start at lower end of dosing range (300 mg/day), titrate slowly with close monitoring of serum levels due to decreased clearance.
No specific dose adjustment but monitor for increased systemic effects; start at lowest effective dose.
No FDA black box warning.
No FDA black box warning.
Narrow therapeutic index; monitor serum theophylline levels to avoid toxicity.,Risk of serious cardiovascular events (e.g., arrhythmias, seizures) at high serum concentrations.,May exacerbate peptic ulcer disease.,Use caution in patients with hypoxemia, hypertension, or heart failure.,Drug interactions: cimetidine, fluoroquinolones, macrolides, and other CYP450 inhibitors increase levels; phenytoin, rifampin, and smoking decrease levels.
Monitor serum theophylline concentrations due to narrow therapeutic index; risk of toxicity at levels >20 mcg/m L; use caution in patients with cardiac disease, hepatic impairment, or seizures; may exacerbate arrhythmias; drug interactions with cimetidine, fluoroquinolones, macrolides, allopurinol, oral contraceptives, smoking, and others.
Hypersensitivity to theophylline or any component of the formulation,Active peptic ulcer disease,Uncontrolled seizure disorders
Hypersensitivity to theophylline or any component; pre-existing cardiac arrhythmias (e.g., ventricular tachycardia); recent myocardial infarction; uncontrolled seizure disorders.
Dietary changes that affect CYP1A2 activity alter theophylline clearance. High-protein, low-carbohydrate diets increase clearance; high-carbohydrate, low-protein diets decrease clearance. Charcoal-broiled meats and cruciferous vegetables (e.g., broccoli, cabbage) induce metabolism, reducing efficacy. Caffeine-containing foods and beverages can potentiate toxicity and should be limited. Consistent dietary habits are critical to maintain stable serum levels.
Avoid significant intake of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase CNS stimulation and risk of toxicity. Charcoal-broiled foods and a high-protein diet may increase clearance. Maintain consistent dietary patterns; avoid extremes of protein/carbohydrate intake.
Theophylline (active ingredient in THEOLAIR) is classified as FDA Pregnancy Category C. Human data do not indicate a major teratogenic risk; however, a small increased risk of congenital anomalies cannot be excluded. First trimester: No consistent evidence of teratogenicity; some studies suggest possible association with cardiac defects. Second/third trimester: May cause fetal tachycardia, irritability, and jitteriness due to transplacental passage; neonatal withdrawal symptoms possible. Avoid use near term if possible.
AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal heart rate, jitteriness, and risk of neonatal apnea with high maternal serum concentrations (>15 mcg/m L). Avoid near term due to prolonged neonatal half-life.
Theophylline is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.72. Concentrations in milk are about 60% of maternal serum. Breastfeeding is generally considered safe if maternal levels are therapeutic; however, irritability and insomnia in infants have been reported. Monitor infant for signs of caffeine-like effects. Use with caution, especially in preterm infants.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach 50% of maternal levels; risk of irritability and sleep disturbances in nursing infants. Use with caution and monitor infant for signs of toxicity.
Pregnancy may decrease theophylline clearance by about 30% due to reduced protein binding and increased volume of distribution, but changes can vary. Dose adjustments should be guided by serum level monitoring. Typical starting dose: 400 mg/day oral, titrated to levels 5–15 mcg/m L. Increased doses may be needed in later pregnancy due to altered pharmacokinetics. Postpartum, clearance may increase, requiring dose reduction.
Pregnancy may increase theophylline clearance due to enhanced hepatic metabolism and increased renal blood flow. Dose adjustments are often required: monitor serum levels regularly and adjust dose to maintain therapeutic levels. Typically, dose may need to be increased by 20-50% in second and third trimesters.
Theophylline (THEOLAIR) has a narrow therapeutic index (5-15 mg/L). Monitor serum levels due to inter- and intra-patient variability. Coadministration with CYP1A2 inhibitors (e.g., cimetidine, fluoroquinolones) or inducers (e.g., phenytoin, smoking) requires dose adjustments. Use with caution in patients with hepatic impairment, congestive heart failure, or fever, as clearance is reduced.
AEROLATE III (theophylline) is a bronchodilator with a narrow therapeutic index; monitor serum levels (target 10-20 mcg/m L). Caffeine and smoking increase clearance; hepatic impairment, heart failure, and certain drugs (e.g., cimetidine, fluoroquinolones) decrease clearance. Avoid use in patients with active peptic ulcer or seizure disorders. Titrate dose slowly to minimize nausea, vomiting, and arrhythmias.
Take exactly as prescribed; do not double the dose if missed.,Avoid changes in smoking habits, diet, or new medications without consulting your doctor.,Report nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Do not consume large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects.,Maintain consistent intake of high-protein or low-protein diets.,Store at room temperature away from moisture and heat.
Take this medication exactly as prescribed; do not crush or chew extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects like jitteriness and insomnia.,Inform your doctor if you experience nausea, vomiting, rapid heartbeat, or seizures.,Do not stop taking this medication abruptly; taper under medical supervision.,Keep all appointments for blood tests to monitor theophylline levels.,Avoid smoking or using nicotine products, as they affect how the medication works.,Carry a list of all medications you take, as many can interact with theophylline.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEOLAIR vs AEROLATE III, answered by our medical review team.
THEOLAIR is a Bronchodilator that works by Theophylline, the active ingredient in THEOLAIR, is a phosphodiesterase inhibitor that increases intracellular c AMP levels, leading to bronchodilation via smooth muscle relaxation. It also has anti-inflammatory effects and may enhance diaphragmatic contractility.. AEROLATE III is a Bronchodilator that works by AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEOLAIR and AEROLATE III depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEOLAIR is: Initial dose: 300 mg orally every 8-12 hours; titrate based on serum theophylline levels to achieve 5-15 mcg/m L. Maintenance: 400-600 mg/day in divided doses.. The standard adult dose of AEROLATE III is: Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEOLAIR and AEROLATE III in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEOLAIR is classified as Category C. Theophylline (active ingredient in THEOLAIR) is classified as FDA Pregnancy Category C. Human data do not indicate a major teratogenic risk; however, a small increased risk of cong. AEROLATE III is classified as Category C. AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.